Search Results for keywords:"Drug Enforcement Administration"

The Drug Enforcement Administration (DEA), part of the Department of Justice, has released a notice regarding an extension of a previously approved information collection related to the registration of those handling controlled substances. This involves DEA Forms 225, 225a, and 225b for businesses and individuals involved in the manufacturing, distribution, or research of controlled substances. The DEA is seeking public comments on the necessity, accuracy, and potential burden of this information collection process, which is estimated to affect 16,560 registrants and require 3,323 hours annually. Comments are welcome until May 27, 2025.

Noramco has applied to the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances, including Poppy Straw Concentrate and an intermediate form of Tapentadol. They plan to use these substances to manufacture other drugs for their customers. As part of their application, they also intend to import synthetic cannabidiol and synthetic Tetrahydrocannabinol, while noting that they will not import finished drugs for commercial sale. The public can submit comments or request a hearing on this application by January 6, 2025.

Patheon API Services, Inc. has applied to the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances. They intend to use these substances as reference standards in research and development for API Manufacturing, and not for any commercial sales. People affected by this application can submit comments or request a hearing by April 28, 2025. All comments must be submitted electronically through the Federal eRulemaking Portal.

Groff NA Hemplex LLC has applied to the Drug Enforcement Administration to become a registered importer of certain controlled substances. These substances will be imported in bulk to produce research-grade materials for clinical trial studies, specifically involving Marihuana Extract compounds. The application process allows for public comments or objections and requests for a hearing until January 13, 2025. The comments should be submitted electronically through the Federal eRulemaking Portal, while hearing requests must be directed to the DEA's office in Springfield, Virginia.

Invizyne Technologies, Inc. has applied to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of certain controlled substances, including synthetic Tetrahydrocannabinols. Stakeholders, such as current manufacturers and applicants, can submit comments or objections electronically through the Federal eRulemaking Portal by March 24, 2025, and may also request a hearing by the same date. The DEA has provided detailed instructions for submitting comments online and has assured that comments will receive a Comment Tracking Number upon successful submission.

The Drug Enforcement Administration (DEA) issued an order to revoke the registration of Dr. Thomas Andr'e Endicott, a dentist in Utah, due to his lack of authority to handle controlled substances after his state licenses were revoked. The DEA's decision is based on the fact that a practitioner must have state authority to dispense controlled substances to maintain DEA registration. Dr. Endicott did not respond to the order, which was served to him through various means, including email. Consequently, his DEA Certificate of Registration is revoked, and any pending registration applications he has are denied.

The Drug Enforcement Administration (DEA) issued an Order to Show Cause and Immediate Suspension of Registrations to Empire Pharmacy and Skyline Pharmacy in Philadelphia, claiming their activities posed an imminent danger to public health. Between 2019 and 2023, the pharmacies failed to maintain accurate records of controlled substances, violating federal and state laws. When the pharmacies did not request a hearing to dispute these claims, the DEA moved forward with final actions to revoke their registrations. Due to their failure to comply and their inadequate responses, the DEA decided to revoke both pharmacies' DEA Certificates of Registration.

In a decision by the Drug Enforcement Administration (DEA), Dr. Michael W. Carlton's Certificate of Registration was revoked due to inappropriate prescribing practices. The DEA found that Dr. Carlton issued 40 prescriptions for controlled substances without establishing a proper doctor-patient relationship and without conducting necessary physical exams, which violated federal and Arizona state laws. Dr. Carlton argued that his practice was standard at the outpatient treatment center where he worked, but the DEA's investigation and expert testimony showed that his actions fell below the standard of care. Consequently, the revocation was seen as necessary to protect public interest.

Siemens Healthcare Diagnostics Inc. has submitted an application to the Drug Enforcement Administration to become a bulk manufacturer of certain controlled substances. The company intends to use these substances to produce products that are exempt from DEA regulations. Individuals or existing registered manufacturers can express their support or objections in writing by March 15, 2021, or request a hearing regarding this application by the same date.

Irvine Labs Inc. has applied to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of certain controlled substances. The application aims to facilitate research and development, as well as distribution to their research customers. The public can submit comments or objections about the application until February 28, 2025, via the Federal eRulemaking Portal. This notice was officially filed and noted by the DEA on December 27, 2024.